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longer-acting opiate. Short-acting opiates, however, have
the potential to reduce time to extubation (TTE) and
may, therefore, decrease length of stay (LOS) and hospi-
tal costs. Remifentanil was added to our institution’s
formulary for use during off-pump bypass surgery. The
objective of this analysis was to compare TTE, LOS
and total hospital costs between patients who received
remifentanil and fentanyl during off-pump bypass sur-
gery. METHODS: The study was prospective and obser-
vational in design. Consecutive patients who underwent
off-pump cardiac bypass surgery and received either
remifentanil or fentanyl from September 1998 to August
1999 were included. Patient charges were converted to
costs using cost-to-charge ratios. The percent of patients
extubated in the operating room (OR), LOS and hospital
costs were compared between the groups. RESULTS:
Baseline demographics, including age, female patients,
co-morbidities and intraoperative variables were similar
between the remifentanil (n  39) and fentanyl (n  20)
groups. Patients given remifentanil during surgery were
significantly more likely to be extubated in the OR than
patients given fentanyl (64% vs. 15%; p  0.001). The
mean LOS was similar in both groups (7.3  3.1d vs. 8.3 
2.7d; p  0.27). Patients who received remifentanil in-
curred lower ward ($3,973  1,719 vs. $4,808  1,794;
p  0.09), recovery room ($31  40 vs. $65  33; p 
0.002) and pulmonary function testing costs ($0  0 vs.
$34  103; p  0.045) than patients who received fenta-
nyl. Anesthesia costs were higher among patients who re-
ceived remifentanil ($476  102 vs. $416  130; p 
0.06). Medical and surgical supplies, OR, ICU, cardiac
catheterization, laboratory, respiratory therapy, phar-
macy, radiology and transfusion costs were similar be-
tween the 2 groups (p  0.05). The total cost was
$15,272  5,556 and $15,616  4,169 in the remifenta-
nil and fentanyl groups, respectively (p  0.81). CON-
CLUSION: Remifentanil, when used in off-pump bypass
surgery, increases the likelihood of extubation in the OR.
However, LOS and total hospital costs remain un-
changed.
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BACKGROUND: Atrial Fibrillation (AF) is the most fre-
quent type of arrhythmia. Termination of acute AF is
generally undertaken in a hospital setting. Available
drugs for termination of acute AF have severe side effects
and complicated dose regimens. There is a need for new
drugs with a high conversion rate, favourable safety pro-
file and easier dosing. OBJECTIVES: To describe the
characteristics and hospital treatment patterns of patients
with AF. To investigate the requirements for an improved
cost-effective anti-arrhythmic therapy. METHODS: A
database was used containing aggregated and anonymised
diagnostic information, hospital experience (e.g., length
of stay), and demographic data for over 80 million inpa-
tient episodes in the UK over ten years. The database
contains 28,524 hospital admissions of patients (65 and
over) with a diagnosis of AF during 1999/2000. 53.3%
are female, with mean length of stay (LOS) 6.1 days;
46.7% are male with LOS 4.3 days. Controlling for age,
the gender LOS difference is significant (p  0.01). RE-
SULTS: Comorbid Conditions. 17.5% of AF patients
also had a diagnosis of chronic ischaemic heart disease
(IHD), a further 7.5% had myocardial ischaemia, and
19.5%, congestive heart failure. Furthermore, 24.2% of
CHF patients and 16.9% of all angina patients also had
clinically significant AF. Cardioversion. Cardioversion
(defibrillation) is used when pharmacological therapy
fails to terminate acute AF. However, significant num-
bers (35%) of cardioversion procedures were undertaken
on an elective day case basis. We are currently investigat-
ing and will report on the resource consequences in acute
AF. CONCLUSIONS: There is a clear unmet medical
need for improved anti-arrhythmic drugs. Using the
dataset, we identify two potentially cost-effective possi-
bilities for improved anti-arrhythmic treatment: an agent
which can simultaneously demonstrate effectiveness in
associated cardiovascular conditions such as IHD or
CHF; or an agent reducing the need for cardioversion in
acute AF.
CV5
THE COST-EFFECTIVENESS OF LIFETIME 
FACTOR VIII PROPHYLAXIS IN THE 
TREATMENT OF SEVERE HEMOPHILIA A
Charles RA1, Hay J2
1University of Southern California, School of Pharmacy, Los 
Angeles, CA, USA; 2University of Southern California, Los 
Angeles, CA, USA
Prophylactic infusion of factor VIII has been shown to
markedly reduce arthropathy in patients with severe he-
mophilia A. OBJECTIVE: The purpose of this model is
to investigate the cost-effectiveness of prophylactic infu-
sion of factor VIII relative to on-demand infusion therapy
in patients with severe hemophilia A. METHODS: Two
hypothetical cohorts were modeled; one cohort receiving
prophylactic and the other on-demand infusions. Factor
VIII infusion therapy begins at age 1 and continues un-
changed over a patient’s lifetime. A recursive Markov
model is used to estimate the expected costs and QALYs
associated with each cohort. Costs and QALYs are calcu-
lated using backward induction in 5-year intervals incor-
porating the DEALE method. Data inputs are estimated
from published literature. The analysis is completed from
a societal perspective, uses a 3% discount rate, with costs
in year 2000 U.S. dollars, and has a time horizon of 50
years. RESULTS: According to the model, patients re-
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ceiving prophylactic therapy experience both higher life-
time costs ($3,542,357) and higher QALYs (18.95) than
patients receiving on-demand therapy ($2,455,268, 15.31).
The ICER was determined to be $298,531/QALY. In the
sensitivity analysis, the ICER was sensitive to the number
of units/kg/yr of factor used per patient, the probability
of arthropathy in years 1 through 5, and the utilities as-
signed. Varying these parameter estimates resulted in an
ICER ranging from $8,315 to $616,158/QALY. CON-
CLUSION: Results from the baseline model indicate that
lifetime prophylactic infusion of factor VIII in patients
with hemophilia is above the generally accepted thresh-
old for cost-effectiveness of $50,000 per QALY. Due to
the model’s sensitivity to the amount of factor used, it is
recommended that pharmacokinetic dosing be explored
to reduce the amount of factor needed to achieve thera-
peutic levels. Research to determine more accurate utili-
ties for persons with hemophilia with and without arth-
ropathy are also needed.
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OBJECTIVES: As low molecular weight heparins
(LMWH)s such as enoxaparin (ENOX) and dalteparin
(DALT) add drug acquisition cost, yet eliminate the need
for activated prothrombin time (aPPT) monitoring com-
pared to unfractionated heparin (UFH), we developed an
economic model to quantify the value of DALT, or
ENOX compared to UFH as cost per clinical event
avoided from an health management organization per-
spective. METHODS: With a hypothetical patient cohort
with confirmed DVT, treatment and clinical outcomes
were modeled using a conventional decision tree over a 6
month timeframe. Treatment with LMWH or UFH con-
tinued for an average of 5 days. Possible clinical events
included thrombocytopenia, major bleed, recurrent VTE,
or death from any cause. Inpatient treatment with UFH
was necessary due to the IV route of administration and
need for apt monitoring. Subcutaneous administration of
LMWHs facilitate early discharge from hospital or treat-
ment in the outpatient setting for the duration. Based on
published sources, we assumed the proportion of patients
receiving LMWH as inpatients, outpatients or with early
discharge were 45%, 30% and 25%, respectively. Drug
efficacy was obtained from a meta-analysis of published
clinical trials. Resource use data associated with drugs
and inpatient and outpatient medical care were obtained
from published sources, treatment guidelines and an ex-
pert physician panel. Medical unit costs (2000 $US) were
obtained from published sources. RESULTS: The base-
line analysis showed DALT and ENOX prevented 28 and
17 clinical events respectively per 1000 patients com-
pared to UFH. The total medical cost per patient treated
with DALT, ENOX and UFH was $3199, $3347, and
$5104, (US$) respectively. Compared to UFH, cost sav-
ings with use of LMWH was attributed to reduced clini-
cal events and fewer hospital days. Sensitivity analysis
showed results were robust. CONCLUSIONS: These fig-
ures indicate that LMWHs provide important improve-
ments with medical cost savings and thus are attractive
both clinically and economically.
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OBJECTIVES: To estimate the cost-effectiveness of the
insulinotropic agent nateglinide vs. metformin using an
epidemiologic risk model that quantifies the relationship
between glucose spikes as measured by 2 hour postpran-
dial blood glucose (2h-BG) and risks for all cause mortal-
ity, acute myocardial infarction (AMI), and stroke in dia-
betic patients. METHODS: We used data from the
DECODE study database (N  22,474, with up 25 years
of follow-up) to estimate parametric failure time models
predicting the risk for death, AMI, and stroke for 2h-BG,
and other CVD risk factors. The risk equations were used
to develop a decision model that projected risks, costs,
and years of life for up to 40 years for men and women
with and without an intervention specifically to control
2h-BG (results for men with 2h-BG 11 mmol/L re-
ported below). Costs included the intervention and the
costs of CVD events. All costs are expressed in Swiss
francs (CHF), and were discounted at 3%. Clinical effi-
cacy was taken from a randomised clinical trial of nateg-
linide versus metformin. RESULTS: When results were
projected for 15, 25, and 40 years, incremental costs
were 9,137, 10,047, 10,133 CHF, respectively (1 CHF 
$0.60). Discounted years of life saved for these same in-
tervals were 0.15, 0.24, and 0.26. The ratios of cost per
year of life saved were 59,600, 41,500, 38,400 CHF.
CONCLUSIONS: Initial modeling suggests that therapy
with nateglinide among individuals with elevated levels
of 2h-BG reduces the risk for death and CVD events and
has acceptable cost-effectiveness ratios compared to met-
formin.
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